Key Milestones

Completed a Phase I/IIa clinical trial of YN001 in healthy subjects and patients with coronary AS in China;
Had a Type C meeting with the FDA at which the FDA indicated that it would be open to considering an accelerated approval program for YN001 based on NCPV as a RLSE

Received the IND approval from the FDA for YN002 to identify high-risk plaques in carotid, cerebral or peripheral arteries in adult patients

Received IND approval from the NMPA with respect to YN001 for the treatment of ASCVD;
Completed the safety evaluation study of YN001 in healthy subjects in China;
Initiated a Phase I/IIa clinical trial of YN001 in healthy subjects and patients with coronary AS in China;
Received orphan drug designation from the FDA with respect to YN003;
Completed the construction of our manufacturing facility in Shanghai

Received IND approval from the FDA with respect to YN001 for the treatment of AS;
Initiated a Phase I clinical trial of YN001 in healthy subjects in Australia

Our pilot-scale laboratory in Beijing commenced operations

Beijing Inno Medicine Co., Ltd. (北京茵诺医药科技有限公司) (formerly known as Beijing Inno Technology Co., Ltd. (北京茵诺科技有限公司)) was established